Trends in annual price for disease-modifying therapies for multiple sclerosis; 1997 to 2021

### Self-administered injections

<table>
<thead>
<tr>
<th>Drug</th>
<th>5 Year Change*</th>
<th>1 Year Change**</th>
<th>Annual Price 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betaseron</td>
<td>35.6%</td>
<td>3.0%</td>
<td>$106,401</td>
</tr>
<tr>
<td>Avonex</td>
<td>30.0%</td>
<td>2.0%</td>
<td>$93,672</td>
</tr>
<tr>
<td>Rebif</td>
<td>48.3%</td>
<td>11.3%</td>
<td>$115,359</td>
</tr>
<tr>
<td>Extavia</td>
<td>23.7%</td>
<td>0.0%</td>
<td>$81,079</td>
</tr>
<tr>
<td>Plegridy</td>
<td>30.0%</td>
<td>2.0%</td>
<td>$93,672</td>
</tr>
<tr>
<td>Kesimpta</td>
<td></td>
<td></td>
<td>$83,000</td>
</tr>
</tbody>
</table>

### Glatiramer Acetate

- Copaxone 20: 7.9% change, 0.0% change, $86,554
- Copaxone 40: 7.9% change, 0.0% change, $75,816
- Glatopa: -71.1% change, 0.0% change, $18,250
- Glat Acet (Mylan): 0.0% change, $18,250

### Oral DMTs

- Gilenya: 41.6% change, 5.0% change, $110,660
- Aubagio: 31.8% change, 5.1% change, $98,054
- Tecfidera: 37.6% change, 0.0% change, $100,690
- Mayzent: 5.0% change, $98,036
- Mavenclad: 12.4% change, $120,742
- Vumerity: 4.0% change, $91,520
- Zeposia: 4.5% change, $89,870
- Bafiertam: $69,770
- Dimethyl fumarate: $3,650

### Infusions

- Tysabri: 35.2% change, 8.9% change, $97,032
- Lemtrada: 27.9% change, 4.8% change, $84,168
- Ocrevus: 3.0% change, $66,950

Notes: Annual price estimated from wholesale acquisition costs (First Databank)
Market entrance date in parenthesis
Dashed line is projected annual price of Betaseron assuming only inflationary increases in price (CPI)
Lemtrada is based on four 12 mg vials (Package insert dosing: 12 mg/day (5 vials) for five consecutive days in first year; 12 mg/day (3 vials) for three days in year 2);
*2016 to 2021 (February); **2020 to 2021 (February). ***Lowest price dimethyl fumarate reported
Updated 2.18.2021 (Data through February 2021)